復星醫藥(02196.HK)通過向復宏漢霖生產基地追加不逾8.18億人幣
復星醫藥(02196.HK)公佈,董事會通過向復宏漢霖生物醫藥產業化基地(二)一期項目增加第3階段投資,不超過8.18億元人民幣(下同),公司擬對建設項目中的3號生產樓由臨牀生產大樓,改爲商業化生產大樓,因此而增加一條原液生產線、並新增購置工藝設備等。
本次建設項目預計總投資金額不超過25.38億元。截至今年10月,該項目包括第一階段和第二階段已累計投入約5.9億元,目前已完成樁基工程,2幢主要生產樓已完成結構封頂、主體結構驗收和所有建築部分的施工,生產輔助樓的結構封頂以及主體結構驗收工作完成,原液線及製劑線等主要生產設備全面啓動工廠驗收測試。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.